http://www.marketwatch.com/story/voluntary-recall-of-hylenex-initiated-2010-05-17?reflink=MW_news_stmp
An excerpt:
DEERFIELD, Ill., May 17, 2010 (BUSINESS WIRE) -- Baxter International Inc. /quotes/comstock/13*!bax/quotes/nls/bax (BAX 42.65, +0.20, +0.47%) announced today that a voluntary recall of all manufactured lots of HYLENEX recombinant (hyaluronidase human injection) has been initiated as a precautionary measure due to instances of particulate matter observed in a limited number of HYLENEX vials during routine stability testing. Baxter is working with the product's NDA-holder, Halozyme Therapeutics, to investigate the root cause of the issue and appropriately address the situation.
To date, no medical events or customer complaints associated with this issue have been reported. Baxter and Halozyme are committed to quickly and appropriately addressing the situation.
The companies have notified the U.S. Food and Drug Administration, and Baxter will be contacting customers to request the return of product. The company estimates that there are approximately 3,500 vials in the marketplace.
The particulate matter has not been found in testing that occurs at the time of product release (that is, immediately following production). Routine stability testing is conducted on samples of commercial products stored under various conditions to verify the quality of the product over time. As part of this stability testing for HYLENEX recombinant, a limited number of vials were observed to contain small, flake-like particles, identified as glass. The companies are continuing to investigate the root cause of this issue.
HYLENEX recombinant is a tissue permeability modifier indicated as an adjuvant in subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; and in subcutaneous urography for improving resorption of radiopaque agents.
Baxter licenses the HYLENEX recombinant technology from Halozyme, which discovered and completed development work to secure FDA approval. Baxter has worldwide exclusive rights to market and sell HYLENEX recombinant, a standalone formulation of recombinant human hyaluronidase. Baxter provides Halozyme with fill/finish services in connection with the manufacture of this product. Baxter and Halozyme launched HYLENEX in October 2009 in the United States for use in pediatric rehydration.
Recent BAX News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:27:02 AM
- Baxter Announces Definitive Agreement to Divest Its Vantive Kidney Care Segment to Carlyle for $3.8 Billion • Business Wire • 08/13/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 11:20:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 11:18:23 AM
- Baxter Reports Second-Quarter 2024 Results • Business Wire • 08/06/2024 11:15:00 AM
- US Index Futures Rise After Market Sell-off, Oil Prices Trim Losses • IH Market News • 08/06/2024 09:49:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 08:46:05 PM
- Baxter to Host Second-Quarter 2024 Financial Results Conference Call for Investors • Business Wire • 07/17/2024 08:15:00 PM
- Baxter Declares Quarterly Dividend • Business Wire • 07/16/2024 08:45:00 PM
- Baxter publishes annual corporate responsibility report, highlighting continued focus on creating lasting impact • Business Wire • 07/10/2024 12:30:00 PM
- Paramount-Skydance $28B Merger, Boeing Agrees to Plead Guilty with $243.6M Fine, and More News • IH Market News • 07/08/2024 10:37:52 AM
- Baxter to Present at Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/06/2024 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:03:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:03:24 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/31/2024 12:10:44 PM
- New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years • Business Wire • 05/29/2024 12:45:00 PM
- Baxter to Present at Jefferies 2024 Global Healthcare Conference • Business Wire • 05/23/2024 08:15:00 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 05/15/2024 06:42:42 PM
- Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive • Business Wire • 05/15/2024 06:00:00 PM
- Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication • Business Wire • 05/13/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 08:36:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 08:36:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 08:35:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 08:35:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 08:34:47 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM